Research progress in lymph node dissection for pancreatic cancer in the era of neoadjuvant therapy

doi:10.3877/cma.j.issn.2095-3232.2024.05.008

Abstract

Abstract:

Pancreatic cancer is characterized with high-degree malignancy and poor prognosis, which is likely to metastasize. Lymph node metastasis is an important factor affecting clinical prognosis of pancreatic cancer patients. Scholars at home and abroad have conducted extensive studies on the range and quantity of lymph node dissection during pancreatic cancer surgery, whereas it is still effective in improving clinical prognosis of pancreatic cancer patients. In recent years, with the change of the concept of comprehensive tumor treatment, the application of neoadjuvant therapy has captivated increasing attention in pancreatic cancer, which has significantly enhanced clinical prognosis of patients. However, whether the number and range of lymph node dissection should be further optimized for patients receiving neoadjuvant therapy remains controversial, which should be supported and improved by more evidence-based medical data, thereby providing better therapeutic effect for patients with pancreatic cancer.

Key words: Pancreatic neoplasms, Pancreatic duct adenocarcinoma, Lymphadenectomy, Lymph node ratio, Neoadjuvant therapy

Ti Zhou, Jia Wu, Fang Han, Linwei Xu, Yuhua Zhang. Research progress in lymph node dissection for pancreatic cancer in the era of neoadjuvant therapy[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 634-639.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2024.05.008

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2024/V13/I05/634

Figures/Tables 2

References 25

[1]	Schnelldorfer T, Ware AL, Sarr MG, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?[J]. Ann Surg, 2008, 247(3):456-462.
[2]	Okusaka T, Nakamura M, Yoshida M, et al. Clinical practice guidelines for pancreatic cancer 2019 from the Japan pancreas society: a synopsis[J]. Pancreas, 2020, 49(3):326-335.
[3]	Marmor S, Burke EE, Portschy PR, et al. Lymph node evaluation for treatment of adenocarcinoma of the pancreas[J]. Surg Oncol, 2015, 24(3):284-291.
[4]	Burke EE, Marmor S, Virnig BA, et al. Lymph node evaluation for pancreatic adenocarcinoma and its value as a quality metric[J]. J Gastrointest Surg, 2015, 19(12):2162-2170.
[5]	Tol JAMG, Gouma DJ, Bassi C, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS)[J]. Surgery, 2014, 156(3):591-600.
[6]	Benassai G, Mastrorilli M, Mosella F, et al. Significance of lymph node metastases in the surgical management of pancreatic head carcinoma[J]. J Exp Clin Cancer Res, 1999, 18(1):23-28.
[7]	Gockel I, Domeyer M, Wolloscheck T, et al. Resection of the mesopancreas (RMP): a new surgical classification of a known anatomical space[J]. World J Surg Oncol, 2007, 5:44.
[8]	Seufferlein T, Uhl W, Kornmann M, et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phaseⅡ trial of the AIO pancreatic cancer group[J]. Ann Oncol, 2023, 34(1):91-100.
[9]	Wu W, Wang XA, Wu X, et al. Total mesopancreas excision for pancreatic head cancer: analysis of 120 cases[J]. Chin J Cancer Res, 2016, 28(4):423-428.
[10]	Safi SA, Haeberle L, Fluegen G, et al. Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival[J]. Pancreatology, 2021, 21(4):787-795.
[11]	Ramia JM, De-la-Plaza R, Manuel-Vazquez A, et al. Systematic review of the mesopancreas: concept and clinical implications[J]. Clin Transl Oncol, 2018, 20(11):1385-1391.
[12]	Wang Z, Ke N, Wang X, et al. Optimal extent of lymphadenectomy for radical surgery of pancreatic head adenocarcinoma: 2-year survival rate results of single-center, prospective, randomized controlled study[J]. Medicine, 2021, 100(35):e26918.
[13]	杨尹默. 胰十二指肠切除术中淋巴结清扫范围争议与共识[J].中国实用外科杂志, 2016, 36(8):843-846.
[14]	Strasberg SM, Drebin JA, Linehan D. Radical antegrade modular pancreatosplenectomy[J]. Surgery, 2003, 133(5):521-527.
[15]	Doi R, Kami K, Ito D, et al. Prognostic implication of para-aortic lymph node metastasis in resectable pancreatic cancer[J]. World J Surg, 2007, 31(1):147-154.
[16]	Sakai M, Nakao A, Kaneko T, et al. Para-aortic lymph node metastasis in carcinoma of the head of the pancreas[J]. Surgery, 2005, 137(6):606-611.
[17]	Safi SA, Rehders A, Haeberle L, et al. Para-aortic lymph nodes and ductal adenocarcinoma of the pancreas: distant neighbors?[J]. Surgery, 2021, 170(6):1807-1814.
[18]	Sperti C, Gruppo M, Blandamura S, et al. Para-aortic node involvement is not an independent predictor of survival after resection for pancreatic cancer[J]. World J Gastroenterol, 2017, 23(24):4399-4406.
[19]	Hempel S, Plodeck V, Mierke F, et al. Para-aortic lymph node metastases in pancreatic cancer should not be considered a watershed for curative resection[J]. Sci Rep, 2017, 7(1):7688.
[20]	Birrer DL, Golcher H, Casadei R, et al. Neoadjuvant therapy for resectable pancreatic cancer: a new standard of care. pooled data from 3 randomized controlled trials[J]. Ann Surg, 2021, 274(5):713-720.
[21]	Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase Ⅲ PREOPANC trial[J]. J Clin Oncol, 2020, 38(16):1763-1773.
[22]	Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial[J]. JAMA Oncol, 2018, 4(7):963-969.
[23]	Macedo FI, Picado O, Hosein PJ, et al. Does neoadjuvant chemotherapy change the role of regional lymphadenectomy in pancreatic cancer survival?[J]. Pancreas, 2019, 48(6):823-831.
[24]	Barrak D, Villano AM, Moslim MA, et al. Total neoadjuvant treatment for pancreatic ductal adenocarcinoma is associated with limited lymph node yield but improved ratio[J]. J Surg Res, 2022, 280:543-550.
[25]	Rahim MK, Okholm TLH, Jones KB, et al. Dynamic CD8⁺ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes[J]. Cell, 2023, 186(6):1127-1143, e18.

组别	胰头癌（胰十二指肠切除术）	胰体尾癌（远端胰体尾切除）
第1站	8a，8p，13a，13b，17a，17b	10，11p，11d，18
第2站	5，6，12a，12b，12p，14p，14d	7，8a，8p，9，14p，14d
第3站	1，2，3，4，7，9，10，11p，11d，15，16a2，16b1，18	5，6，12a，12b，12p，13a，13b，15，17a，17b，16a2，16b1

组别	胰头癌（胰十二指肠切除术）	胰体尾癌（远端胰体尾切除）
第1站	8a，8p，13a，13b，17a，17b	10，11p，11d，18
第2站	5，6，12a，12b，12p，14p，14d	7，8a，8p，9，14p，14d
第3站	1，2，3，4，7，9，10，11p，11d，15，16a2，16b1，18	5，6，12a，12b，12p，13a，13b，15，17a，17b，16a2，16b1

Please choose a citation manager

Content to export